-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
It is reported that the Human Resources Research Center of 51job Worry-free recently launched the "2022 Resignation and Salary Adjustment Research Report".
The research report shows that the overall turnover rate of employees in 2021 is 18.
8%, which is a 4.
0% increase compared with 2020.
Obviously
.
Among them, the voluntary turnover rate reached 14.
1% in 2021, an increase of 6.
0 percentage points from 2020
.
The analysis believes that the main reason for the increase in the voluntary turnover rate of employees is that the epidemic has been effectively controlled
.
In terms of salary adjustments, in 2021, 88.
4% of companies chose salary adjustments, a substantial increase from 2020
.
The company's salary adjustment rate was 6.
2%, an increase from 2020 (4.
7%)
.
Among them, high-tech, biomedicine, and financial industries are among the top salary adjustments
.
The report pointed out that this is mainly related to the relatively small impact of the epidemic in these industries, the strong demand for professional and technical personnel, and the strong ability to pay
.
As far as the pharmaceutical industry is concerned, according to the "2021 Corporate Salary Adjustment Data Reference Manual" issued by CIIC Consulting in April, in the 2021 survey data, companies have resumed normal operations, and more than 70% of the companies have salary adjustment plans, of which 23 % Of companies’ salary adjustment budgets have increased from last year
.
According to the analysis of CIIC Consulting, the salary increase rate in the pharmaceutical and health industry is obvious, rising from 7.
2% in 2020 to 7.
4% in 2021.
Among them, the salary increase rate of professional and technical personnel is the highest, with a salary increase rate of 8%; followed by Supervisors, sales staff and managers have increased salaries by 7.
4%, 7.
3% and 7.
2% respectively.
In addition, the total cash income of employees in the pharmaceutical research and development industry is generally higher
.
At that time, the analysis believed that in 2021, companies will pay more attention to salary adjustments based on the performance structure, which will increase from 50% to 69%
.
In the pharmaceutical industry, due to the impact of the epidemic, on-site drug promotion activities in 2020 are forced to be postponed or transferred online.
Drugs that are not related to the epidemic also have an impact on sales due to restricted offline sales activities, which also affects performance.
Sales staff with salary structure
.
According to a research report released by CIIC Consulting in September, the salary adjustment rate for the pharmaceutical/healthcare industry in 2021 is 7.
6%.
.
The pharmaceutical and medical industry is affected by the positive impact of the epidemic, and the salary adjustment rate in 2021 is relatively high
.
Judging from the above two data of CIIC Consulting, the salary adjustment rate of the pharmaceutical industry in 2021 has stabilized at more than 7%, and it seems to be rising in the second half of the year
.
Since the beginning of this year, the pharmaceutical industry has continued to report salary increases for pharmaceutical companies
.
For example, in May, it was revealed that the salaries of Harbin Pharmaceuticals executives increased year by year, and this year's salary increases reached 1.
38 million
.
According to the financial report data, in the three years from 2018 to 2020, the company's directors, supervisors and senior management personnel
.
The total pre-tax remuneration was 8.
97 million yuan, 19.
2243 million yuan, and 22.
1152 million yuan, achieving three increases in three years.
According to the news in the first half of the year, Cinda plans to increase salary by an average of 10%.
It is understood that the increase in most pharmaceutical companies is generally 0- 15%, the median salary increase is about 5%-10%, and Cinda Bio's 10% salary increase is also impressive
.
In addition, Taiji Group recently agreed to adjust the allowance standard for independent directors of the company from 60,000 yuan per person per year (after tax) to 160,000 yuan per person per year (pre-tax), with a salary increase of 167%
.
It is reported that after the salary increase, the Taiji Group will earn 160,000 yuan (before tax) in subsidies per person per year
.
In addition to local pharmaceutical companies, multinational pharmaceutical companies also have plans to issue salary increases in 2021
.
For example, Eli Lilly and Company raised its salary in March this year, with an average increase of about 10% planned
.
According to relevant information in April of this year, the Roche Diagnostics program has an average increase of 6-8%; the Johnson & Johnson Ethicon program has an average increase of about 5.
5%; Sanofi plans to increase its salary by 5-7%
.
The research report shows that the overall turnover rate of employees in 2021 is 18.
8%, which is a 4.
0% increase compared with 2020.
Obviously
.
Among them, the voluntary turnover rate reached 14.
1% in 2021, an increase of 6.
0 percentage points from 2020
.
The analysis believes that the main reason for the increase in the voluntary turnover rate of employees is that the epidemic has been effectively controlled
.
In terms of salary adjustments, in 2021, 88.
4% of companies chose salary adjustments, a substantial increase from 2020
.
The company's salary adjustment rate was 6.
2%, an increase from 2020 (4.
7%)
.
Among them, high-tech, biomedicine, and financial industries are among the top salary adjustments
.
The report pointed out that this is mainly related to the relatively small impact of the epidemic in these industries, the strong demand for professional and technical personnel, and the strong ability to pay
.
As far as the pharmaceutical industry is concerned, according to the "2021 Corporate Salary Adjustment Data Reference Manual" issued by CIIC Consulting in April, in the 2021 survey data, companies have resumed normal operations, and more than 70% of the companies have salary adjustment plans, of which 23 % Of companies’ salary adjustment budgets have increased from last year
.
According to the analysis of CIIC Consulting, the salary increase rate in the pharmaceutical and health industry is obvious, rising from 7.
2% in 2020 to 7.
4% in 2021.
Among them, the salary increase rate of professional and technical personnel is the highest, with a salary increase rate of 8%; followed by Supervisors, sales staff and managers have increased salaries by 7.
4%, 7.
3% and 7.
2% respectively.
In addition, the total cash income of employees in the pharmaceutical research and development industry is generally higher
.
At that time, the analysis believed that in 2021, companies will pay more attention to salary adjustments based on the performance structure, which will increase from 50% to 69%
.
In the pharmaceutical industry, due to the impact of the epidemic, on-site drug promotion activities in 2020 are forced to be postponed or transferred online.
Drugs that are not related to the epidemic also have an impact on sales due to restricted offline sales activities, which also affects performance.
Sales staff with salary structure
.
According to a research report released by CIIC Consulting in September, the salary adjustment rate for the pharmaceutical/healthcare industry in 2021 is 7.
6%.
.
The pharmaceutical and medical industry is affected by the positive impact of the epidemic, and the salary adjustment rate in 2021 is relatively high
.
Judging from the above two data of CIIC Consulting, the salary adjustment rate of the pharmaceutical industry in 2021 has stabilized at more than 7%, and it seems to be rising in the second half of the year
.
Since the beginning of this year, the pharmaceutical industry has continued to report salary increases for pharmaceutical companies
.
For example, in May, it was revealed that the salaries of Harbin Pharmaceuticals executives increased year by year, and this year's salary increases reached 1.
38 million
.
According to the financial report data, in the three years from 2018 to 2020, the company's directors, supervisors and senior management personnel
.
The total pre-tax remuneration was 8.
97 million yuan, 19.
2243 million yuan, and 22.
1152 million yuan, achieving three increases in three years.
According to the news in the first half of the year, Cinda plans to increase salary by an average of 10%.
It is understood that the increase in most pharmaceutical companies is generally 0- 15%, the median salary increase is about 5%-10%, and Cinda Bio's 10% salary increase is also impressive
.
In addition, Taiji Group recently agreed to adjust the allowance standard for independent directors of the company from 60,000 yuan per person per year (after tax) to 160,000 yuan per person per year (pre-tax), with a salary increase of 167%
.
It is reported that after the salary increase, the Taiji Group will earn 160,000 yuan (before tax) in subsidies per person per year
.
In addition to local pharmaceutical companies, multinational pharmaceutical companies also have plans to issue salary increases in 2021
.
For example, Eli Lilly and Company raised its salary in March this year, with an average increase of about 10% planned
.
According to relevant information in April of this year, the Roche Diagnostics program has an average increase of 6-8%; the Johnson & Johnson Ethicon program has an average increase of about 5.
5%; Sanofi plans to increase its salary by 5-7%
.
